ALNY ALNYLAM PHARMACEUTICALS INC revenue, earnings and financials

For the quarter ended June 30, 2026, ALNYLAM PHARMACEUTICALS INC reported revenue of $1.29B (up 66.9% from a year earlier), net income of $164M and diluted EPS of $1.21; for the fiscal year ended December 2025 revenue was $3.71B, up 65.2% on the year before.

ALNY annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $3.71B, gross profit n/a, operating income $502M, net income $314M (margin 8.4%), EPS $2.33
• Fiscal year ended Dec 2024: revenue $2.25B, gross profit n/a, operating income −$177M, net income −$278M (margin -12.4%), EPS −$2.18
• Fiscal year ended Dec 2023: revenue $1.83B, gross profit n/a, operating income −$282M, net income −$440M (margin -24.1%), EPS −$3.52
• Fiscal year ended Dec 2022: revenue $1.04B, gross profit n/a, operating income −$785M, net income −$1.13B (margin -109.0%), EPS −$9.30
• Fiscal year ended Dec 2021: revenue $844M, gross profit n/a, operating income −$709M, net income −$853M (margin -101.0%), EPS −$7.20

ALNY quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $1.29B (up 66.9% year over year), net income $164M, EPS $1.21
• Quarter ended Mar 31, 2026: revenue n/a, net income $206M, EPS n/a
• Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income $153M, EPS n/a
• Quarter ended Sep 30, 2025: revenue $1.25B (up 149.3% year over year), net income $251M, EPS $1.84
• Quarter ended Jun 30, 2025: revenue $774M (up 17.3% year over year), net income −$72.2M, EPS −$0.55
• Quarter ended Mar 31, 2025: revenue n/a, net income −$18.3M, EPS n/a
• Quarter ended Dec 31, 2024 (from the annual report): revenue $593M (up 34.9% year over year), net income −$83.8M, EPS −$0.66
• Quarter ended Sep 30, 2024: revenue $501M (down 33.3% year over year), net income −$112M, EPS −$0.87
• Quarter ended Jun 30, 2024: revenue $660M (up 107.0% year over year), net income −$16.9M, EPS −$0.13
• Quarter ended Mar 31, 2024: revenue $494M (up 54.8% year over year), net income −$65.9M, EPS −$0.52
• Quarter ended Dec 31, 2023 (from the annual report): revenue $440M (up 31.2% year over year), net income −$138M, EPS −$1.06
• Quarter ended Sep 30, 2023: revenue $751M (up 184.0% year over year), net income $148M, EPS $1.15
• Quarter ended Jun 30, 2023: revenue $319M (up 41.8% year over year), net income −$276M, EPS −$2.21
• Quarter ended Mar 31, 2023: revenue $319M (up 49.7% year over year), net income −$174M, EPS −$1.40
• Quarter ended Dec 31, 2022 (from the annual report): revenue $335M (up 29.6% year over year), net income −$207M, EPS −$1.69
• Quarter ended Sep 30, 2022: revenue $264M (up 40.9% year over year), net income −$406M, EPS −$3.32
• Quarter ended Jun 30, 2022: revenue $225M (up 1.9% year over year), net income −$277M, EPS −$2.29
• Quarter ended Mar 31, 2022: revenue $213M (up 20.1% year over year), net income −$240M, EPS −$2.00
• Quarter ended Dec 31, 2021 (from the annual report): revenue $259M, net income −$258M, EPS −$2.16
• Quarter ended Sep 30, 2021: revenue $188M, net income −$205M, EPS −$1.72

ALNY cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow $524M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$8.31M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow $104M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$541M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$642M, share buybacks n/a

ALNY balance sheet

• Jun 30, 2026: cash $1.71B, total assets $5.56B, total liabilities $4.20B, shareholders' equity $1.35B
• Dec 31, 2025: cash $1.66B, total assets $4.97B, total liabilities $4.18B, shareholders' equity $789M
• Sep 30, 2025: cash $1.49B, total assets $4.85B, total liabilities $4.62B, shareholders' equity $234M
• Jun 30, 2025: cash $1.11B, total assets $4.57B, total liabilities $4.32B, shareholders' equity $555M
• Mar 31, 2025: cash n/a, total assets $4.21B, total liabilities $4.10B, shareholders' equity $426M
• Dec 31, 2024: cash $966M, total assets $4.24B, total liabilities $4.17B, shareholders' equity $67.1M
• Sep 30, 2024: cash $1.10B, total assets $4.21B, total liabilities $4.17B, shareholders' equity $32.4M
• Jun 30, 2024: cash $968M, total assets $4.01B, total liabilities $4.01B, shareholders' equity −$3.07M

What is ALNY's revenue?

ALNYLAM PHARMACEUTICALS INC reported $3.71B of revenue for the fiscal year ended December 2025.

Is ALNY profitable?

Yes. ALNYLAM PHARMACEUTICALS INC earned $775M over the last four quarters.

ALNY ownership and insider trades · All stocks